<DOC>
	<DOCNO>NCT00002828</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness raltitrexed fluorouracil treat patient colorectal cancer metastatic , recurrent , surgically remove .</brief_summary>
	<brief_title>Chemotherapy With Raltitrexed Fluorouracil Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose raltitrexed administer fluorouracil patient advance colorectal carcinoma . II . Determine toxicity safety regimen patient . III . Assess , preliminary manner , antitumor activity regimen patient . OUTLINE : This dose-escalation study raltitrexed . Patients receive raltitrexed IV 15 minute follow 24 hour later fluorouracil IV . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos raltitrexed maximum tolerate dose ( MTD ) determine . The MTD define dose immediately precede 2 6 patient experience dose-limiting toxicity . An additional 6-10 patient treat MTD . Patients follow 6 week . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 5-20 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic , locally recurrent , surgically unresectable colorectal carcinoma Measurable disease No CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time normal ( 5 time normal know liver metastasis ) Renal : Creatinine great 1.5 mg/dL Other : No severe concurrent infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen Prior fluorouracilbased regimen advance colorectal cancer allow Prior fluorouracil radiotherapy consider therapy advance disease At least 4 week since prior chemotherapy ( 8 week mitomycin nitrosoureas ) recover Endocrine therapy : No concurrent steroid except antiemesis replacement therapy Radiotherapy : See Chemotherapy No prior radiotherapy 30 % bone marrow Surgery : See Disease Characteristics At least 4 week since prior surgery unless fully recover Other : No concurrent vitamin supplement contain folic acid No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>